When patients ask for "Botox", they are often referring to a treatment rather than a specific product. In the UK, practitioners have access to several licensed botulinum toxin type A products, each with different formulations, unit systems, and clinical profiles. Understanding those differences — and why they matter — is the first step to an informed treatment decision.
The Same Active Ingredient, Different Products
All aesthetic botulinum toxin type A products work by the same mechanism: they temporarily block the release of acetylcholine at the neuromuscular junction, preventing muscle contraction and thereby softening dynamic expression lines. The active ingredient is identical. What differs is how the neurotoxin complex is formulated, stabilised, and measured.
The UK's main licensed aesthetic botulinum toxin products are Botox (Allergan/AbbVie), Azzalure (manufactured by Ipsen, commercialised by Galderma), and Bocouture (Merz Aesthetics). Botox and Bocouture use mouse units (MU) as their dose measurement. Azzalure uses Speywood Units (sU) — a different biological activity scale. This distinction is not academic: the unit systems are not interchangeable, and practitioners who do not understand this risk significant over- or under-dosing if they switch products without adjusting doses accordingly.
Azzalure: The Clinical Profile
Azzalure is the branded aesthetic product derived from Ipsen's Dysport formulation — a botulinum toxin with over 20 years of consistent manufacturing history. Its regulatory approval for aesthetic use was based on clinical trials involving more than 2,600 patients, with pivotal Phase III placebo-controlled studies demonstrating significant reduction in moderate-to-severe glabellar lines for up to four months, with effect persisting significantly in one pivotal study at five months.
The median time to onset of response with Azzalure is two to three days, with maximum effect typically observed at day 30. This is slightly faster than some patients report with Botox, though individual variation is considerable. The protein complex of Azzalure is also somewhat smaller, which may influence diffusion characteristics — some practitioners prefer Azzalure precisely because of its diffusion profile in certain anatomical areas.
The Importance of Dose and Placement
The real determinant of a good anti-wrinkle result is not which product is used but how precisely it is placed, in what dose, and by a practitioner who understands the individual patient's facial anatomy. The same product in different hands produces entirely different outcomes. The goal at Cosmetica is always to understand the patient's specific muscle anatomy, their aesthetic goals, and their previous treatment history before determining product, dose, and injection pattern.
At the natural end of the spectrum, the aim is to soften lines while preserving movement — a delicate balance that requires careful dose management and a thorough understanding of antagonist and agonist muscle relationships. Full relaxation is a different clinical goal and requires a different approach. Both are entirely legitimate outcomes; which is right depends entirely on the patient.
Prescription-Only for Good Reason
Botulinum toxin is a prescription-only medicine (POM) under UK law. It must be prescribed by a regulated healthcare professional — a doctor, dentist, nurse prescriber or pharmacist independent prescriber — following a face-to-face consultation. Clinics that offer botulinum toxin without a prescription, or via a remote prescriber who never meets the patient, are operating outside the law. This is one of the clearest reasons to ensure your practitioner is a regulated healthcare professional: it is the one treatment where the legal framework already offers substantial patient protection.